NCT05750628 - Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria | Biotech Hunter

Enrollment

327

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

June 9, 2026

Study Completion Date

June 23, 2026

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Interventions

DRUG

INE963

oral INE963

DRUG

KAE609 (Cipargamin)

oral KAE609 (Cipargamin)

DRUG

SoC (Coartem)

DRUG

KLU156

oral sachet KLU156 (KAF156 + lumefantrine)

Trial Locations (12)

10102

RECRUITING

Novartis Investigative Site, Tororo

40100

RECRUITING

Novartis Investigative Site, Ahero

RECRUITING

Novartis Investigative Site, Kisumu

92037

RECRUITING

Novartis Investigative Site, Kintampo

Unknown

RECRUITING

Novartis Investigative Site, Banfora

RECRUITING

Novartis Investigative Site, Kampala

BP 18

RECRUITING

Novartis Investigative Site, Nanoro

13BP972

RECRUITING

Novartis Investigative Site, Abidjan

BP 173

RECRUITING

Novartis Investigative Site, Azaguié

BP 242

RECRUITING

Novartis Investigative Site, Lambaréné

BP 1437

RECRUITING

Novartis Investigative Site, Libreville

VWJ6+8WF

RECRUITING

Novartis Investigative Site, Navrango